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This study compared the plasma amprenavir pharmacokinetics of the human immunodeficiency virus (HIV)
protease inhibitors amprenavir (Agenerase) 1,200 mg twice daily (BID) and the amprenavir prodrug
GW433908, a formulation that substantially reduces the number of tablets per dose compared with amprena-
vir, at doses of 1,395 mg and 1,860 mg BID, in combination with abacavir 300 mg BID and lamivudine 150 mg
BID in patients with HIV infection. Overall, 78 patients received study treatment. Compared with amprenavir
1,200 mg BID, both GW433908 1,395 mg BID and GW433908 1,860 mg BID delivered equivalent steady-state
(ss) values for area under the plasma amprenavir concentration-time curve (AUC) at the end of a dosing
interval (), lower maximum plasma amprenavir concentrations (30% lower), and higher plasma amprenavir
concentrations at the end of a dosing interval (28% higher for GW433908 1,395 mg BID and 46% higher for
GW433908 1,860 mg BID). Time-variant plasma amprenavir pharmacokinetics were observed with reductions
in plasma amprenavir exposure over the first 4 weeks of dosing; the decrease in plasma amprenavir AUC,ss
versus the AUC from 0 h to  was 27% for GW43308 1,395 mg, 45% for GW433908 1,860 mg, and 23% for
amprenavir 1,200 mg. All three regimens reduced plasma HIV-1 RNA (2 log10 copies/ml) and increased CD4

cell counts (100 cells/mm3) over the initial 28 days. Adverse event profiles were consistent with those
previously reported for amprenavir. Although not statistically tested, the GW433908 groups appeared to have
fewer gastrointestinal symptoms. In conclusion, the protease inhibitor GW433908 delivered comparable
plasma amprenavir concentrations to those delivered by amprenavir 1,200 mg BID. GW433908, in combination
with abacavir and lamivudine, demonstrated potent antiviral activity and was generally well tolerated over a
4-week period.
The importance of human immunodeficiency virus (HIV)-
infected patients adhering to their treatment regimens is well
recognized. A number of studies have shown that suboptimal
adherence is linked with poor treatment outcomes in combi-
nation regimens, whether or not they include HIV protease
inhibitors (4, 7, 8). There are many factors that affect the level
of patient adherence, and one of these is the number of pills in
the treatment regimen. For example, a previous meta-analysis
showed a negative correlation between the number of pills in a
treatment regimen and the proportion of patients achieving
plasma HIV type 1 (HIV-1) RNA concentrations of 50 cop-
ies/ml after 48 weeks of treatment (J. Bartlett, R. Demasi, J.
Quinn, C. Moxham, and F. Rousseau, 7th Conf. Retrovir.
Opportunistic Infect., abstr. 519, 2000). Therefore, reducing
the number of pills that patients are required to take could
have a beneficial effect on antiretroviral treatment outcomes.
GW433908 (908), a prodrug of the HIV-1 protease inhibitor
amprenavir (APV; Agenerase), is a calcium phosphate ester
that is rapidly hydrolyzed by alkaline phosphatase at the intes-
tinal brush border to form APV and inorganic phosphate. This
leads to APV absorption with minimal 908 available systemi-
cally (3). Because it has higher water solubility than APV, 908
can be formulated into high-strength film-coated tablets com-
pared with APV, which is formulated as 150-mg soft gelatin
capsules. Thus, the number of 908 tablets required per dose is
reduced substantially compared with APV (when administered
as Agenerase), giving the potential to improve patient adher-
ence.
Previous single-dose studies conducted in healthy adult sub-
jects have shown that 908 1,395 mg delivers an equivalent
plasma APV exposure (area under the concentration-time
curve from 0 h to infinity [AUC0–]) and an approximately 30
to 40% lower maximum plasma APV concentration (Cmax)
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than APV capsules at a dose of 1,200 mg (3). Prior to the study
reported here, the pharmacokinetics of 908 had not been an-
alyzed in HIV-infected individuals.
In this study, HIV-1-infected patients were randomized to
receive 908 or APV in combination with the nucleoside reverse
transcriptase inhibitors abacavir and lamivudine. Previous
studies of some HIV-infected patients suggest that gut levels of
alkaline phosphatase may be lower than those found in healthy
subjects (1, 13). Consequently, it was considered possible that
levels of cleavage of 908 could be lower in the gut of HIV-
infected patients than healthy volunteers, resulting in lower
blood levels of APV. For this reason, two doses of 908 were
used in this study (1,395 mg and 1,860 mg twice daily [BID]) to
help determine the appropriate dosing regimen for further
study. The primary objectives of this study were to compare the
pharmacokinetic parameters of APV in HIV-infected patients
after repeat dosing with 908 and APV. Further, the safety,
tolerability, and initial antiviral effect of the two doses of 908
BID were assessed when given to HIV-infected patients for 28
days.
(The results of this study were previously presented in part
at the Eighth Conference on Retroviruses and Opportunistic
Infections, 4 to 8 February 2001, Chicago, Ill.)
MATERIALS AND METHODS
Patients. Male and nonpregnant female, HIV-1-infected patients were eligible
to participate in the study if they were 18 to 65 years of age, were protease
inhibitor naïve, and had 4 weeks of prior therapy with either nucleoside reverse
transcriptase inhibitors or nonnucleoside reverse transcriptase inhibitors. Pa-
tients were also to have plasma HIV-1 RNA concentrations of at least 5,000
copies/ml documented in the 28 days before drug administration. Patients were
not excluded if they were smokers. All women used adequate contraception
during the study. All patients gave written informed consent to participate in the
study.
Patients were excluded if they had diabetes, congestive heart failure, cardio-
myopathy, or other cardiac dysfunction. Patients were also ineligible for the study
if they had a malabsorption syndrome or other gastrointestinal dysfunction that
could interfere with drug absorption or a history of clinically relevant pancreatitis
or hepatitis within the previous 6 months. Other exclusion criteria included a
history of any drug or other allergy felt by the investigator to be clinically
significant; current alcohol or illicit drug use; a clinical diagnosis of Centers for
Disease Control and Prevention (CDC) AIDS category C; or standard laboratory
values outside normal reference ranges. Finally, subjects were excluded if treat-
ment with the following medications occurred within 14 days before starting the
study with 908 or if there was an anticipated need during the study: astemizole,
bepridil, cisapride, dihydroergotamine, ergotamine, midazolam, terfenadine, triazo-
lam, rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, erythromycin,
clarithromycin, ketoconazole, itraconazole, cimetidine, lovastatin, simvastatin, cer-
ivastatin, atorvastatin, pravastatin, fluvastatin, sildenafil, dexamethasone, troglita-
zone, primidone, ethosuximide, pimozide, flecainide, propofenone, amiodarone, and
quinidine.
Study design. This was a partially double-blinded (with respect to 908 dose),
randomized, repeat-dose, crossover study (protocol number APV20001). The
study ran from 15 October 1999 to 11 May 2000 and was conducted in 11 centers
in Europe, 8 in the United States, and 1 in South Africa. A national, regional, or
investigational center ethics committee or institutional review board approved
the study protocol at each site. The study was done in accordance with Good
Clinical Practice and the Declaration of Helsinki guidelines applicable at the
time. The primary endpoints of the study included a comparison of the following
pharmacokinetic parameters after repeat dosing of 908 and APV: AUC of APV
during a dosing interval, , at steady state (AUC,ss), APV concentration at the
end of a dosing interval at steady state (trough concentration; Cmin,ss), and APV
Cmax at steady state (Cmax,ss). Other endpoints were to assess the safety and
tolerability of 908, the change in plasma HIV-1 RNA concentration, and the
change in CD4 cell counts after 28 days of treatment with 908 or APV, in
combination with the nucleoside reverse transcriptase inhibitors abacavir and
lamivudine.
Patients were screened up to 28 days before the start of study treatment. On
day 1 of the study, patients attended the clinical research unit and were random-
ized to receive one of the following three treatments for 28 days: 908 at 1,395 mg,
908 at 1,860 mg, or APV at 1,200 mg. They received a single dose of their study
medication on day 1 and BID dosing from day 2 onwards. At day 28, patients
crossed over treatments for an additional 14 days according to the schedule in
Table 1. Patients who received either of the 908 doses in treatment period 1 (days
1 to 28) crossed over to APV 1,200 mg in treatment period 2 (day 29 to 42);
patients who received APV 1,200 mg in treatment period 1 crossed over to one
of the 908 doses, according to the randomization schedule. Investigators and
patients were blinded to the dose of 908 by using a double-dummy technique.
Patients were randomized using a central randomization procedure (Clinphone,
Nottingham, United Kingdom). Study personnel called the 24-h Clinphone ser-
vice at least 7 days before a patient’s anticipated enrollment date and were given
a treatment number to assign to the patient.
The 908 1,395-mg dose was administered as three 465-mg tablets, and the
1,860-mg dose was administered as four 465-mg tablets. Each 465-mg tablet of
908 contained the molar equivalent of 400 mg of APV. To ensure that patients
were blinded to which dose of 908 they received, those randomized to 908 1,395
mg also received one matched placebo tablet so that all patients received four
tablets for their 908 dose. The selection of the two doses of 908 was based on
preliminary data from a phase I study in healthy male volunteers (3). APV
(Agenerase; GlaxoSmithKline) was administered as eight 150-mg soft gel cap-
sules BID. All patients received abacavir (Ziagen; GlaxoSmithKline; one 300-mg
tablet BID) plus lamivudine (Epivir; GlaxoSmithKline; one 150-mg tablet BID)
in combination with their study drug.
The patients fasted for 8 h before pharmacokinetic sampling on days 1, 28, and
42. Fifteen serial whole-blood samples were taken at specified time points for
pharmacokinetic analysis over the first 24 h after dosing on day 1. At the end of
each dosing period (days 28 and 42), 14 timed whole-blood samples were taken
over 12 h. If a cannula were used for collection, it was inserted into an arm vein
within sufficient time before dosing. Precautions were taken to prevent dilution
of blood samples. In centers where the cannula was kept patent with normal
saline or heparin flushes, an initial 0.5- to 1.0-ml volume of blood was discarded
before collecting each sample to ensure that samples were not diluted by the
saline or heparin flushes. Alternatively, a mandril system was used in the cannula,
thus avoiding the use of heparin (Madrin-Intocan Braun Melsugen AG). The
cannula was removed after the last blood sample was collected. Blood samples
were collected in 2.7-ml sodium citrate-containing (blue-top) Vacutainer tubes,
gently inverted after collection, and refrigerated at 4°C. Plasma was collected
after refrigerated centrifugation at 2,000  g for 10 min within 1 h of sample
collection. Plasma samples were frozen at 20°C or lower in a non-self-defrost-
ing freezer, where they were stored until shipping for analysis on dry ice.
At screening and at days 1, 7, 14, 21, 28, and 42, blood samples were collected
for determination of plasma HIV-1 RNA, CD4 cell counts, and clinical labo-
ratory tests, and data were collected on HIV-associated conditions and adverse
events. Plasma HIV-1 RNA was measured using the Roche Amplicor HIV-1
Ultrasensitive Monitor test (primers 1.0; limit of detection  50 copies/ml).
Samples with plasma HIV-1 RNA levels of 	75,000 copies/ml were retested
using the Roche Amplicor HIV-1 Monitor test (primers 1.0; standard assay limit
of detection  400 copies/ml). CD4 cell counts were measured using flow
cytometry.
Adverse events and serious adverse events were recorded throughout the
study. Adverse events were graded according to their severity using a four-point
AIDS Clinical Trials Groups scale, with a score of 4 being the most severe.
At the end of the 42-day pharmacokinetic study, patients could continue in an
open-label phase and receive a combination regimen of APV, abacavir, and
lamivudine. Results from this phase will be the subject of a separate publication.
TABLE 1. Summary of dosages and dosing
Group Treatment period 1(days 1–28)a
Treatment period 2
(days 29–42)a
1 908, 1,395 mg BID APV, 1,200 mg BID
2 APV, 1,200 mg BID 908, 1,395 mg BID
3 908, 1,860 mg BID APV, 1,200 mg BID
4 APV, 1,200 mg BID 908, 1,860 mg BID
a 908 and APV were both administered in combination with abacavir (300 mg
BID) and lamivudine (150 mg BID).
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Statistical and pharmacokinetic analysis. A sample size of 24 patients in the
combination of treatment groups 1 and 2 and in the combination of treatment
groups 3 and 4 (48 patients total; Table 1) was selected as the number of subjects
that would provide greater than 90% power at the one-sided 5% level to detect
a 20% decrease in AUC,ss after administration of 908 compared with APV
based on the highest intrasubject standard deviation (0.24) observed in prior
APV studies. To obtain additional safety and efficacy data and ensure that 48
evaluable patients completed the study, 84 patients were to be enrolled. The
study was not powered to test any hypothesis related to clinical efficacy or safety,
and therefore only descriptive statistics are presented.
The pharmacokinetic summary population consisted of patients who had
plasma APV pharmacokinetic parameter values on days 1, 28, and 42 of the
study. The intent-to-treat (ITT), exposed population consisted of all patients who
were randomized into the study with documented evidence of having consumed
study drug. For the analysis of safety data, the safety population consisted of all
patients randomized in the study with the exception of any patients who did not
take any study drug.
Values for the single-dose plasma APV pharmacokinetic parameters were
estimated as follows. The Cmax and the first time to reach Cmax (tmax) were the
actual observed values. The apparent terminal plasma elimination rate constant
(
z) was estimated from log-linear regression analysis of the terminal phase of
the plasma concentration-time profile. The associated apparent terminal elimi-
nation half-life (t1/2) was calculated as follows: t1/2  ln2/
z. The AUC to the last
sample time (AUClast) and AUC0– were calculated by the log-linear trapezoidal
method.
Values for the steady-state plasma APV pharmacokinetic parameters were
estimated as follows. The maximum concentration at steady state (Cmax,ss) and
the first time to reach Cmax,ss (tmax,ss) were the actual observed values. The
concentration at the end of a dosing interval at steady state (Cmin,ss) was calcu-
lated as the mean of the predose and 12-h plasma APV concentrations. The
AUC during a dosing interval, , at steady state (AUC,ss) was calculated by the
log-linear trapezoidal method.
Plasma APV pharmacokinetic parameters, except tmax,ss, were loge trans-
formed prior to statistical analyses, and the comparisons were expressed as
geometric least-squared (GLS) mean ratios (with associated 90% confidence
intervals [CI]) on the original scale. Steady-state plasma APV pharmacokinetics
following administration of 908 1,395 mg BID or 908 1,860 mg BID were com-
pared within subject to APV 1,200 mg BID in analysis of variance (ANOVA)
models. Plasma alpha-1 acid glycoprotein (AAG) concentrations were included
as a covariate, treatment was included as a fixed effect, and subject was included
as a random effect using the SAS mixed linear models procedure.
Time variance in plasma APV pharmacokinetics was examined by a within-
subject comparison of AUC,ss on day 28 versus AUC0– on day 1 for each
treatment using ANOVA. The ANOVA model included plasma AAG concen-
trations as a covariate, treatment, day, and the interaction of treatment and day
as fixed effects, and subject as a random effect.
Plasma AAG concentrations, age, body weight, sex, race, hepatitis status,
baseline CD4 count, baseline plasma HIV-1 RNA concentration, and treat-
ment were tested as variables correlated with single-dose (day 1) and steady-state
(days 28 and 42 separately) plasma APV pharmacokinetic parameters in a
correlation analysis using the SAS correlation procedure. The relationship be-
tween change in plasma AAG concentrations and change in plasma APV loge-
transformed AUC,ss values over the first 28 days of the study was examined by
stepwise regression analysis using the SAS regression procedure. In addition, the
relationship between both plasma AAG concentrations and change in plasma
AAG concentrations over the first 28 days of the study and age, body weight, sex,
race, baseline CD4 cell count, baseline plasma HIV-1 RNA concentration,
treatment day (tested with plasma AAG concentrations only), and change in
plasma HIV-1 RNA average AUC minus baseline (tested with the change in
plasma AAG concentrations over the first 28 days only) were examined with
stepwise regression.
RESULTS
Patient disposition and baseline characteristics. Of the 107
patients screened for this study, 85 patients were randomized
and a total of 78 patients received study treatment (Fig. 1).
There were six premature discontinuations: three patients
withdrew consent (two receiving 908 1,395 mg and one receiv-
ing 908 1,860 mg), one patient was lost to follow-up (908 1,395
mg), one patient in the 908 1,860-mg group was unable to
tolerate pharmacokinetic sampling, and one patient in the
APV 1,200-mg group withdrew because of scheduling conflicts.
Baseline characteristics were generally similar across the
treatment groups, with the possible exception of patients ran-
domized to the APV group, who appeared to have a lower
CD4 cell count at baseline and a higher proportion of pa-
tients enrolling with CDC class B HIV infection (Table 2).
Pharmacokinetic analyses. The pharmacokinetic summary
population comprised 53 patients: 22 patients received 908
1,395 mg BID, 31 received 908 1,860 mg BID, and all 53
received APV 1,200 mg BID.
APV pharmacokinetics. The Cmin,ss was approximately 1.28-
fold higher after dosing with 908 1,395 mg than with APV 1,200
mg (GLS mean ratio  1.28, 90% CI  1.06 to 1.54; Table 3).
Plasma APV Cmin,ss was also higher after dosing with 908 1,860
mg BID than with APV 1,200 mg BID (GLS mean ratio 
1.46, 90% CI  1.24 to 1.72; Table 3). Both 908 1,395 mg BID
and 908 1,860 mg BID delivered near-equivalent plasma APV
AUC,ss values and lower Cmax,ss values (30% lower) com-
pared with APV 1,200 mg BID (Table 3). Median steady-state
plasma APV concentration-time profiles at steady state after
administration of 908 and APV are shown in Fig. 2.
Time variance in plasma APV pharmacokinetics was ob-
served for the three regimens (Table 4). The GLS mean
AUC,ss/AUC ratio was 0.73 (90% CI, 0.61 to 0.87) for 908
1,395 mg, 0.55 (90% CI, 0.47 to 0.66) for 908 1,860 mg, and
0.77 (90% CI, 0.65 to 0.91) for APV 1,200 mg.
Plasma AAG concentrations were consistently correlated
with plasma APV AUC,ss and Cmax,ss on days 1 (r
2  0.337 to
0.589), 28 (r2  0.540 to 0.721), and 42 (r2  0.626 to 0.768).
A linear relationship was seen in the percent change in plasma
APV AUC compared to the percent change in AAG from day
28 to day1 (Fig. 3). Age, body weight, sex, race, hepatitis B
and/or C status, baseline CD4 cell count, baseline plasma
HIV-1 RNA concentration, and treatment were also assessed
but found to have no correlation with plasma APV pharmaco-
kinetic parameters.
908 pharmacokinetics. 908 was rapidly converted to APV
with minimal 908 measured systemically. Of the 53 subjects
included in the pharmacokinetic summary population, 29 of 37
patients (78%) who received 908 on day 1 had quantifiable 908
concentrations (10 of 15 patients [67%] who received 908 1,395
mg and 19 of 22 patients [86%] who received 908 1,860 mg).
Thirty-nine out of 53 patients (74%) who received 908 on days
14 to 28 had quantifiable 908 (14 of 22 patients [64%] who
received 908 1,395 mg BID and 25 of 31 patients [81%] who
received 908 1,860 mg BID). Plasma 908 concentrations were
quantifiable between 0.25 and 4 h postdose. Geometric mean
plasma 908 pharmacokinetic parameter values were similar for
the two 908 regimens; AUClast,ss was 0.021 h  g/ml for 908
1,395 mg BID and 0.018 h  g/ml for 1,860 mg BID, and
Cmax,ss was 0.020 g/ml for 908 1,395 mg BID and 0.021 g/ml
for 1,860 mg BID. In all subjects, plasma 908 AUClast,ss was
0.6% of the corresponding APV AUC,ss, and plasma 908
Cmax,ss was 1.6% of the corresponding APV Cmax,ss. 908 was
not detected in plasma at the end of the dosing interval on days
14to 28, i.e., Cmin,ss was below the limit of detection.
Efficacy analyses. The ITT (exposed) population comprised
78 patients: 26 patients received 908 1,395 mg, 29 patients
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received 908 1,860 mg, and 23 patients received APV 1,200 mg
over the first 28 days of the study.
Plasma HIV-1 RNA. Median (range) baseline plasma HIV-1
RNA concentrations were 4.7 log10 copies/ml (2.7 to 6.2 log10
copies/ml) for the 908 1,395-mg group, 4.5 log10 copies/ml (1.8
to 6.4 log10 copies/ml) for the 908 1,860-mg group, and 4.6
log10 copies/ml (3.4 to 6.2 log10 copies/ml) for the APV
1,200-mg group. Median (range) decreases in plasma HIV-1
RNA concentrations were similar for all three groups during the
treatment period: 2.0 log10 copies/ml (3.0 to 0.49 log10 cop-
ies/ml) for the 908 1,395-mg group, 1.9 log10 copies/ml (2.8 to
0.1 log10 copies/ml) for the 908 1,860-mg group, and 2.0 log10
copies/ml (3.4 to 0.7 log10 copies/ml) for the APV 1,200-mg
group after 28 days of treatment (Fig. 4).
FIG. 1. Summary of patient disposition in treatment periods 1 and 2.
TABLE 2. Summary of baseline characteristics for the ITT (exposed) population
Characteristic 908 1,395 mg (n  26) 908 1,860 mg (n  29) APV 1,200 mg (n  23)
Age (yrs) median (min, max) 35 (21, 51) 36 (22, 54) 32 (21, 58)
No. (%) male 17 (65) 20 (69) 16 (70)
Race (n [%])
White 16 (62) 20 (69) 11 (48)
Black 8 (31) 8 (28) 9 (39)
Asian 0 0 1 (4)
Other 2 (8) 1 (3) 2 (9)
Weight (kg) median (min, max) 70.0 (46, 118) 72.3 (52, 105) 65.0 (50, 99)
Plasma HIV-1 RNA (log10 copies/ml) median (min, max) 4.75 (2.71, 6.15) 4.52 (1.78, 6.37) 4.58 (3.43, 6.16)
CD4 cell count (cells/mm3) median (min, max) 245 (16, 1051) 348 (53, 979) 177 (4, 677)
CDC classification (n [%])
A, asymptomatic or lymphadenopathy 16 (62) 20 (69) 7 (30)
B, symptomatic, not AIDS 10 (38) 9 (31) 16 (70)
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One patient in the 908 1,860-mg group had a plasma HIV-1
RNA level of 400 copies/ml on day 1 of the study. This
subject had a screening viral load of 	5,000 copies/ml using the
Roche Amplicor 1.5 HIV-1 Monitor test and was randomized
and treated before it was determined that a non-protocol-
defined assay had been used. The subject screening and day 1
HIV RNA sample were reanalyzed using the Roche Amplicor
HIV-1 Ultrasensitive Monitor test with HIV-1 RNA results of
733 and 60 copies/ml, respectively. This subject continued in
the trial and is included in the efficacy analysis. At day 28, 11
of 26 patients (42%) in the 908 1,395-mg group, 13 of 29
patients (45%) in the 908 1,860-mg group, and 9 of 23 patients
(39%) in the APV 1,200-mg group had plasma HIV-1 RNA of
400 copies/ml.
CD4 cell counts. Median baseline CD4 cell counts were
245 cells/mm3 for the 908 1,395-mg group, 301 cells/mm3 for
the 908 1,860-mg group, and 183 cells/mm3 for the APV
1,200-mg group. Increases in CD4 cell counts were similar for
all three groups during the treatment period: 111 cells/mm3 for
the 908 1,395-mg group, 106 cells/mm3 for the 908 1,860-mg
group, and 92 cells/mm3 for the APV 1,200-mg group at day 28.
Safety analyses. The safety population comprised 78 pa-
tients: 26 patients received 908 1,395 mg, 29 patients received
908 1,860 mg, and 23 patients received APV 1,200 mg.
Grade 2 to 4 (moderate to severe) drug-related adverse
events were generally evenly distributed between the treatment
groups (Table 5), although several gastrointestinal adverse
events appeared to be more common in the APV group than
FIG. 2. Median steady-state plasma APV concentration-time profiles for the 908 1,395-mg BID (; n  22), 908 1,860-mg BID (■ ; n  31),
and APV 1,200-mg (Œ; n  53) groups at the end of treatment period 1 (day 28).
TABLE 3. Summary of APV pharmacokinetic parameters
Parameter
Geometric mean (95% CI), (n) GLS mean ratio (90% CI), (n) for steady-statetreatment comparisons with APV 1,200 mgc
908 1,395 mg 908 1,860 mg APV 1,200 mg 908 1,395 mg 908 1,860 mg
Single dose (day 1)
AUC0– (h  g/ml) 22.8 (18.7–27.8) (15) 42.3 (34.1–52.5) (18) 24.6 (18.9–32.0) (16)
Cmax (g/ml) 4.64 (3.37–6.38) (15) 7.94 (6.55–9.62) (22) 7.19 (5.94–8.72) (16)
tmax (h) 2.5 (1.5,4.0)
a (15) 2.0 (0.5,4.3)a (22) 1.3 (0.5,3.0)a (16)
t1/2 (h) 7.7 (5.9–10.0) (15) 7.9 (6.2–10.0) (18) 9.6 (6.5–14.0) (16)
Steady state (days 28
and 42)
AUC,ss (h  g/ml) 16.5 (13.8–19.6) (22) 17.0 (14.9–19.5) (31) 16.2 (14.3–18.3) (53) 0.96 (0.85–1.09) (22) 1.07 (0.96–1.19) (31)
Cmax,ss (g/ml) 4.82 (4.06–5.72) (22) 4.78 (4.14–5.53) (31) 6.80 (5.90–7.84) (53) 0.70 (0.59–0.82) (22)* 0.73 (0.63–0.85) (31)*
Cmin,ss (g/ml) 0.35 (0.27–0.46) (22) 0.35 (0.27–0.45) (31) 0.26 (0.21–0.31) (53) 1.28 (1.06–1.54) (22)* 1.46 (1.24–1.72) (31)*
tmax,ss (g/ml) 1.3 (0.8,4.0)
a (22) 1.5 (0.8,4.10)a (31) 1.0 (0.5,2.5)a (53) 1.39 (1.08–1.70)b (22)* 1.75 (1.46–2.03)b (31)*
a Data are presented as median (minimum, maximum).
b Data are presented as the least squares mean ration (90% CI).
c *, statistically significant difference between 908 and APV 1,200 mg groups.
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the 908 groups (both groups combined). For days 1 to 28, the
incidence of nausea was 3 of 55 patients (5%) for 908 and 5 of
23 patients (22%) for APV 1,200 mg. The incidence of abdom-
inal pain was 1 in 55 patients (2%) for 908 and 4 of 23 patients
(17%) for APV 1,200 mg. For patients who received 908 from
days 1 to 28, diarrhea (five patients, 9%), hypersensitivity re-
action to abacavir (four patients, 7%), and sleep disorders
(four patients, 7%) were the most frequently reported grade 2
to 4 drug-related adverse events. Nausea (five patients, 22%),
abdominal pain, diarrhea (four patients, 17% [both events]),
and fatigue (three patients, 13%) were the most frequently
reported drug-related adverse events for APV 1,200 mg.
After crossing over (days 29 to 42), the incidence of grade 2
to 4 drug-related adverse events was lower than during days 1
to 28: 4 patients (17%) who received 908 and 16 patients
(29%) who received APV 1,200 mg reported grade 2 to 4
drug-related adverse events. The most frequently reported
grade 2 to 4 drug-related adverse events were diarrhea (one
patient, 4%) for patients who received 908 and diarrhea (four
patients, 7%) and gaseous symptoms and nausea (three pa-
tients each, 5%) for patients who received APV 1,200 mg.
From days 1 to 28, five patients (6%) experienced hypersen-
sitivity reactions to abacavir. One of the patients also experi-
enced an urticarial rash (grade 2) at the same time as the
hypersensitivity reaction.
There was a small difference in the median change from
baseline in blood cholesterol between the treatment arms at
day 28: 0.955 mmol/liter for patients who received 908 versus
0.490 mmol/liter for those who received APV 1,200 mg. How-
ever, this difference was not clinically significant. The median
change in triglyceride concentrations at day 28 was similar for
the two treatment arms: 0.205 mmol/liter for 908 and 0.195
mmol/liter for APV 1,200 mg.
DISCUSSION
In this study, the APV AUC,ss was similar for 908 1,395 mg,
908 1,860 mg, and APV 1,200 mg. For both doses of 908, the
Cmin,ss was statistically significantly higher than that delivered
by APV 1,200 mg under steady-state conditions. The Cmin,ss for
APV 1,200 mg was greater than the previously reported APV
concentration required to inhibit 50% of viral replication that
was determined from clinical isolates of HIV (0.26 g/ml ver-
sus 0.146 g/ml after adjustment for protein binding) (11). The
higher inhibitory quotient of 908 might translate into more
FIG. 3. Percent change in plasma APV AUC versus percent
change in AUC (day 28/day1).
FIG. 4. Median plasma HIV-1 RNA changes from baseline for the
908 1,395-mg (), 908 1,860-mg (■ ), and APV 1,200-mg (Œ) groups in
treatment period 1.
TABLE 4. Summary of plasma APV pharmacokinetics
Parameter
Median (interquartile range)
908 1,395 mg BIDa 908 1,860 mg BIDb APV 1,200 mg BIDc
Single dose
AUC0– (h  g/ml) 20.3 (16.4–27.4) 45.6 (38.1–52.5) 23.3 (17.4–32.6)
Cmax (g/ml) 5.29 (3.29–7.42) 8.61 (6.94–10.66) 7.37 (5.29–8.46)
tmax (h) 2.5 (1.5–3.0) 1.9 (1.3–2.5) 1.3 (1.0–1.8)
t1/2 (h) 6.4 (5.6–11.2) 7.2 (5.0–9.8) 6.8 (6.5–12.9)
Steady state
AUC,ss (h  g/mL) 16.5 (12.6–21.3) 16.9 (13.9–21.9) 16.5 (12.0–21.4)
Cmax,ss (g/ml) 4.67 (3.92–6.52) 4.82 (3.71–5.8) 7.01 (4.67–9.27)
C,ss (g/ml) 0.305 (0.249–0.539) 0.340 (0.189–0.502) 0.246 (0.186–0.365)
tmax,ss (h) 1.2 (1.0–2.0) 1.5 (0.8–2.5) 1.0 (0.8–1.0)
a n  15 for single-dose values; n  22 for steady-state values.
b n  18 for single-dose values, except for Cmax and t1/2, for which n was 22; n  31 for steady-state values.
c n  16 for single-dose values; n  53 for steady-state values.
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favorable antiviral activity and durability. As the Cmax obtained
after administering both doses of 908 was significantly lower
than that for APV 1,200 mg, this could lead to further in-
creases in tolerability, because a lowered Cmax may decrease
the incidence of gastrointestinal adverse drug effects, as was
suggested but not conclusively demonstrated by this study.
908 was rapidly converted to APV, with minimal 908 avail-
able systemically (0.6% of corresponding APV AUC and
1.6% of corresponding APV Cmax,ss). This finding is consis-
tent with data observed in a previous single-dose 908 study
conducted in healthy adult subjects (3).
It appears that there were disproportionately higher in-
creases in plasma APV AUC0– and Cmax values after admin-
istration of a single dose of 908 1,860 mg compared with a
single dose of 908 1,395 mg. Although 908 1,860 mg delivered
higher plasma APV exposures than 908 1,395 mg following
single-dose administration, both doses were equivalent to APV
1,200 mg BID with respect to plasma APV AUC,ss upon
multiple dose administration for 28 days. Plasma APV AUC
values decreased between day 1 and day 28 for all three treat-
ments; however, the proportional decrease for the 908
1,860-mg treatment was the largest (approximately 23% for
APV 1,200 mg BID, 26% for 908 1,395 mg, and 46% for 908
1,860 mg BID).
The reason for the differential decrease in plasma APV
AUC,ss between the two 908 treatments is not fully understood.
There are a number of possible reasons, including the following:
saturation of absorption, saturation of hydrolysis (conversion of
908 to APV), induction of P-glycoprotein (decreased absorption
of APV), induction of cytochrome P450 (CYP) 3A4 (increased
metabolism of APV), and/or the disproportionately higher base-
line plasma APV exposure for subjects receiving 908 1,860 mg on
day 1. If saturation of absorption was involved, the single-dose
plasma APV pharmacokinetics would have been similar for the
two 908 doses. However, there were obvious differences in plasma
APV exposure between single doses of 908 1,395 mg and 1,860
mg. If saturation of hydrolysis was involved, day 28 plasma 908
concentrations would have been higher for 908 1,860 mg than for
908 1,395 mg BID. However, no difference was observed between
the doses.
APV induced CYP3A4 and P-glycoprotein in rats that re-
ceived 139 and 450 mg of APV/kg/day for 14 days (5). Induc-
tion effects have not been demonstrated in other animal spe-
cies but have been seen in humans (2, 6, 12; R. Bertz, C. Foit,
D. Burt, A. Hsu, Y.-L. Chiu, T. Chira, R. Wieboldt, L. A.
Williams, G. R. Granneman, and E. Sun. Prog. Abstr. 3rd Int.
Workshop Clin. Pharmacol. HIV Ther., abstr. 7.6, 2002). The
ability to evaluate the metabolic induction potential of APV in
HIV-infected patients is confounded by reductions in plasma
AAG concentrations as patients are effectively treated. Plasma
AAG concentrations were consistently correlated with plasma
APV pharmacokinetics on each of days 1, 28, and 42 in this
study; this finding is consistent with previous analyses (10).
Changes in plasma AAG concentrations and changes in
plasma APV AUC,ss values over the first 28 days of the study
were significantly correlated, confirming the observation of a
previous study (11). These data indicate that changes in plasma
APV pharmacokinetics over time may be due, in part, to
changes in plasma AAG concentrations as well as an inductive
effect on either P-glycoprotein or CYP3A4.
In this study, all treatments were generally well tolerated
and the adverse event profiles were generally consistent with
those previously reported for APV (9): the most frequently
reported adverse events were nausea, diarrhea, and abdominal
pain for patients on APV and diarrhea and sleep disorders for
patients on 908. Notably, the proportion of patients reporting
nausea and abdominal pain were lower in the 908 groups than
the APV 1,200-mg group. Further large-scale studies are under
way to fully define the safety profile of 908.
Across all study regimens, through just 28 days of therapy,
plasma HIV-1 RNA concentrations were rapidly reduced by
about 2 log10 copies/ml and CD4
 cell counts increased by
about 100 cells/mm3. These early potency results are promis-
ing, and further studies are ongoing to determine the long-
term efficacy of 908.
Providing patients with a protease inhibitor with a low pill
count is likely to facilitate adherence and, subsequently, im-
prove treatment outcome (4, 8). Since conducting this study, a
700-mg 908 tablet has become available that is bioequivalent to
the 465-mg tablet (GlaxoSmithKline, personal communica-
tion) and delivers the equivalent of 600 mg of APV. Therefore,
a dosing regimen of four 700-mg tablets per day is likely to
result in similar APV levels to the 908 1,395-mg BID dose and,
by extension, similar antiretroviral activity.
In conclusion, 908 is a promising protease inhibitor that was
administered at doses of 1,395 mg (three tablets) BID and
1,860 mg (four tablets) BID in this study. 908 delivered equiv-
alent APV exposure to APV 1,200 mg and provided Cmin,ss
values above the APV 50% inhibitory concentration value pre-
viously determined for clinical isolates of HIV. 908 demon-
strated potent antiviral activity by reducing plasma HIV-1
RNA concentrations and increasing CD4 cell counts and was
generally well tolerated over the period studied.
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Hôpital Cochin Tarnier, Paris, France; and Christain Trepo, Hôpital
Hôtel Dieu, Lyon, France. We thank Justin Cook for editing and
writing assistance during preparation of the manuscript.
GlaxoSmithKline Research and Development provided support for
this study.
REFERENCES
1. Asmuth, D. M., S. M. Hammer, and C. A. Wanke. 1994. Physiological effects
of HIV infection on human intestinal epithelial cells: an in vitro model for
HIV enteropathy. AIDS 8:205–211.
2. Bart, P. A., P. G. Rizzardi, S. Gallant, K. P. Golay, P. Baumann, G. Pantaleo,
and C. B. Eap. 2001. Methadone blood concentrations are decreased by the
administration of abacavir plus APV. Ther. Drug Monit. 23:553–555.
3. Falcoz, C., J. M. Jenkins, C. Bye, K. B. Kenney, S. Studenberg, H. Fuder, and
W. T. Prince. 2002. Pharmacokinetics of GW433908, a prodrug of APV, in
healthy male volunteers. J. Clin. Pharmacol. 42:887–898.
4. Haubrich, R. N., S. J. Little, J. S. Currier, D. N. Forthal, C. A. Kemper, G. N.
Beall, D. Johnson, M. P. Dube, J. Y. Hwang, J. A. McCutchan, et al. 1999.
The value of patient-reported adherence to antiretroviral therapy in predict-
ing virologic and immunologic response. AIDS 13:1099–1107.
5. Huang, L., S. A. Wring, J. L. Woolley, K. R. Brouwer, C. Serabjit-Singh, and
J. W. Polli. 2001. Induction of P-glycoprotein and cytochrome P450 3A by
HIV protease inhibitors. Drug Metab. Dispos. 29:754–760.
6. Justesen, U. S., N. A. Klitgaard, K. Brosen, and C. Pedersen. 2003. Phar-
macokinetic interaction between amprenavir and delavirdine after multiple-
dose administration in healthy volunteers. Br. J. Clin. Pharmacol. 55:100–
106.
7. Le Moing, V., G. Chene, M. P. Carrieri, A. Alioum, F. Brun-Vezinet, L.
Piroth, J. P. Cassuto, J. P. Moatti, F. Raffi, C. Leport, et al. 2002. Predictors
of virological rebound in HIV-1-infected patients initiating a protease inhib-
itor-containing regimen. AIDS 16:21–29.
8. Paterson, D. L., S. Swindells, J. Mohr, M. Brester, E. N. Vergis, C. Squier,
M. M. Wagener, and N. Singh. 2000. Adherence to protease inhibitor ther-
apy and outcomes in patients with HIV infection. Ann. Int. Med. 133:21–30.
9. Pedneault, L., C. Brothers, G. Pagano, P. Tymkewycz, J. Yeo, J. Millard, and
A. Fetter. 2000. Safety profile and tolerability of APV in the treatment of
adult and pediatric patients with HIV infection. Clin. Ther. 22:1378–1394.
10. Sadler, B. M., C. Gillotin, Y. Lou, and D. S. Stein. 2001. In vivo effect of
1-acid glycoprotein on pharmacokinetics of APV, a human immunodefi-
ciency virus protease inhibitor. Antimicrob. Agents Chemother. 45:852–856.
11. Sadler, B. M., C. Gillotin, Y. Lou, and D. S. Stein. 2001. Pharmacokinetic
and pharmacodynamic study of the human immunodeficiency virus protease
inhibitor APV after multiple oral dosing. Antimicrob. Agents Chemother.
45:30–37.
12. Tran, J. Q., C. Petersen, M. Garrett, M. Schultz-Smith, B. Hee, J. Lil-
libridge, and B. M. Kerr. 2001. Pharmacokinetic interaction between dela-
virdine and reduced dose amprenavir in HIV negative adults following mul-
tiple dosing. Clin. Infect. Dis. 33:1170.
13. Ullrich, R., W. Heise, C. Bergs, M. L’age, E. O. Riecken, and M. Zeitz. 1992.
Effects of zidovudine treatment on the small intestinal mucosa in patients
infected with the human immunodeficiency virus. Gastroenterology 102:
1483–1492.
VOL. 48, 2004 GW433908 IN HIV-INFECTED PATIENTS 123
